Sporadically, patients with a proven defect in either mFAO or OXPHOS are described presenting with a metabolic profile and clinical phenotype expressing concurrent defects in both pathways. Biochemical linkages between both processes are tight. Therefore, it is striking that concurrent dysfunction of both systems occurs so infrequently. In this review, the linkages between OXPHOS and mFAO and the hypothesized processes responsible for concurrent problems in both systems are reviewed, both from the point of view of primary biochemical connections and secondary cellular responses, i.e. signaling pathways constituting nutrient-sensing networks. We propose that affected signaling pathways may play an important role in the phenomenon of concurrent defects. Recent data indicate that interference in the affected signaling pathways may resolve the pathological phenotype even though the primary enzyme deficiency persists. This offers new (unexpected) prospects for treatment of these inborn errors of metabolism.
INTRODuCTION
Inborn errors of metabolism arise from single enzyme deficiencies but behave as complex traits 1 .
The broad spectrum of clinical presentations that can be observed in patients with the same enzyme deficiency is a clear example of this. Apparently, cellular metabolism and physiology have many ways to adapt to perturbations in biochemical pathways, and each of these (mal-) adaptations comes with their own set of clinical symptoms. Unbiased '-omics' approaches i.e. transcriptomics and metabolomics, can be of great help to go beyond textbook biochemistry and generate hypotheses concerning possible mechanisms that account for these adaptations. Only recently application ofthese approaches to the field of inborn errors of metabolism has started in the field of mitochondrial diseases.
In the mitochondrion, mFAO, OXPHOS, and the tricarboxylic acid (TCA) cycle function together in the formation of adenosine triphosphate (ATP). Mitochondrial FAO takes care of the repetitive shortening of acyl-CoA esters for the generation of acetyl-CoA, NADH, and FADH 2 . OXPHOS is the process of ATP synthesis via the transfer of electrons from NADH and FADH 2 , which have been generated in mFAO or the TCA cycle, to oxygen over the electron transport chain (ETC). According to textbook biochemistry, this continuous regeneration of NAD + and FAD by the ETC and oxidation of the acetyl-residue of acetyl-CoA in the Krebs cycle to release free CoA (CoASH) are essential for the Table 1 . Clinical characteristics of OXPHOS and mFAO defects.
OxPhOS defects mFAO defects

Metabolic profile
Lactic acidemia, worsening upon glucose administration (Hypo)ketotic hypoglycemia Abnormal acylcarnitine profile Secondary free carnitine deficiency Organic aciduria 110 mFAO to proceed. It is inherent to this that dysfunctional OXPHOS should accompany impairment of mFAO. However, the opposite is observed. In humans, deficiencies in many of the enzymes important in mFAO and OXPHOS have been described 2, 3 . When defects and resulting clinical symptoms are considered, mFAO and OXPHOS usually behave as independently functioning systems (for reviews on individual mFAO and OXPHOS defects and their respective clinical presentation we refer to Table 1 and [3] [4] [5] [6] [7] [8] . It is sporadically observed that patients with an established OXPHOS or mFAO defect present with clinical symptoms or metabolite patterns that imply concurrent defects in both systems. The question then arises what molecular mechanisms determine this sporadic occurrence of signs of a combined defect.
In this review we like to distinguish between two major responses of the body to defects in mFAO and OXPHOS; the 'primary biochemical linkages' and 'secondary cellular response' . In Figure 1 we depict several levels of integration. At the metabolic level the conversion of substrates into biomass, energy, and products takes place. At this level all biochemical reactions take place, as well as the metabolite-driven regulation of enzyme activity. Until now, the concurrence of mFAO and OXPHOS defects has mainly been discussed at the level of 'primary biochemical linkages' , i.e. at this metabolic In the next paragraphs, we will first discuss the known primary biochemical and structural linkages between OXPHOS and mFAO, the reported clinical cases and related in vitro studies on presentation of concurrent OXPHOS and mFAO dysfunction. Next, we will discuss the emerging literature on 'secondary cellular responses' , and their role in mitochondrial metabolism. Moreover, we will suggest possible interventions in the pathological signaling as new treatment options.
PRIMARy BIOChEMICAL LINkAGES BETwEEN OxPhOS AND MFAO
Biochemically, mFAO and OXPHOS are coupled by the TCA cycle, complex I of the ETC and electron transfer flavoprotein (ETF) (Figure 2 its electrons directly to complex I of the ETC. FADH 2 is oxidized by transfer of electrons to ETF. Reduced ETF subsequently transfers its electrons to ETF-ubiquinone oxidoreductase (ETF-QO), which donates the electrons to the ETC via ubiquinone (UQ) 9 ( Figure 2 ).
During electron transfer through the ETC, an electrochemical proton gradient over the inner mitochondrial membrane is generated, and subsequently dissipated while ATP is formed by complex V (Figure 2 Proteins involved in OXPHOS and mFAO are not only linked kinetically via metabolite concentrations, but they also associate into physical complexes. In humans, attachment of VLCAD to the inner mitochondrial membrane enables a direct interaction between mFAO and OXPHOS 17, 18 . ETF-QO is also attached to the inner mitochondrial membrane 19 , and has in pig liver been found to form a socalled "supercomplex" with MCAD, ETF, UQ, and complex III 9 . Furthermore, "supercomplexes" between complex I of the ETC and HADH, and complex I and VLCAD were identified in pig heart mitochondria 20, 21 . The acyl-CoA dehydrogenase (ACAD) proteins have also been found associated with OXPHOS "supercomplexes", in which various ETC complexes are assembled in one large complex for presumably more efficient electron transport and limiting reactive oxygen species formation 9, [22] [23] [24] [25] .
DEFECTS IN OxPhOS ASSOCIATED wITh SECONDARy FATTy ACID OxIDATION DEFECTS
The complex interrelationships between OXPHOS and mFAO have been underlined in studies showing that defects in OXPHOS sporadically lead to secondary mFAO inhibition. Most commonly, primary biochemical links and altered ratios are put forward as an explanation for these observations 16, [26] [27] [28] [29] . We will present the reported clinical symptoms according to the primary defect.
Complex I -NADH dehydrogenase defects
The clinical phenotype in patients with complex I deficiency is highly variable (Table 1) 30 . Only a few patients have been reported with signs of a combined complex I and secondary HADH dysfunction, presenting with hepatosplenomegaly, cardiomyopathy, and muscle weakness. Biochemically, lactic acidosis, increasing blood lactate after an oral glucose bolus, and a low KB/FFA ratio corresponding to 7 hypoketosis during hypoglycemia have been reported 31 . Organic acids in the urine showed elevated concentrations of lactate and 3-hydroxydicarboxylic acids during hypoglycemia. LCHAD and SCHAD activities were normal, whereas complex I activity measured in lymphoblasts was severely lowered 27, 29, [32] [33] [34] .
In vitro studies underlined these clinical findings, as oxidation of labeled hexadecanoic acid (C 16:0 ) was found to be decreased in cultured skin fibroblasts of a group of patients with a complex I deficiency when tritium release of [9,10(n)-3 H 2 ]-C 16:0 was measured 35, 36 . Acylcarnitine analysis in cultured skin fibroblasts of two patients with identified mtDNA mutations causing complex I deficiency showed multiple acyl-CoA dehydrogenase deficiency (MADD)-like profiles with mildly elevated concentrations of C 4 -carnitine, and high concentrations of C 6 -and C 8 -carnitine 37 .
Complex II -Succinate dehydrogenase defects
Two patients with a primary defect in complex II have been described presenting with lactic acidosis, cardiomyopathy, hypotonia, and hepatomegaly. In vitro resembling acylcarnitine profiles seen in MADD 16, 37 . Selective SCAD and MCAD deficiency were excluded. Besides lowered complex II activities, activities of complexes III and IV were also mildly reduced 16 .
Complex III -Cytochrome bc 1 complex defects
Only one patient with an isolated complex III deficiency has been described presenting with a hypoglycemia, lactic acidosis and moderate hepatomegaly after prolonged fasting with gastro-enteritis 38 .
The hypoglycemia responded well to glucose infusion. Upon a fasting tolerance test again hypoglycemia and lactic acidosis developed. KB concentrations and organic acid profiles were normal. FAO in cultured skin fibroblasts was normal, and complex III deficiency was identified by enzyme and mutation analysis 38 .
In vitro studies in rat heart mitochondria acutely inhibited with myxothiazol, an inhibitor of complex III, underlined the reported clinical findings. Upon hexadecanoyl-CoA (C 16 -CoA) oxidation, titration with myxothiazol led to accumulation of metabolites that typically accumulate in HADH dysfunction.
Direct effects of myxothiazol on MTP enzyme activity were excluded by enzyme assays. When the concentration of myxothiazol was further increased above 0.2 μM, concentrations of the abovementioned intermediates decreased and concentrations of C 16 -CoA and -carnitine increased, indicating impaired flux through VLCAD 26, 36 . That mild inhibition of complex III affects mFAO primarily through HADH, fits with the very low equilibrium constant of HADH, which makes the mFAO more sensitive to the NADH/NAD + than to the FADH 2 /FAD ratio 39 .
Complex IV -Cytochrome c oxidase defects
Various clinical presentations indicating secondary mFAO inhibition resulting from complex IV deficiency have been described. Similar to what has been described for complex I and III deficiencies, two patients presented with a hypoglycemia. One of these patients presented with hypoglycemia, elevated lactate concentrations and high KB concentrations already after a short-term fast (4 hours). Mitochondrial FAO was not studied in cultured skin fibroblasts of this patient. In contrast, the second patient presented with a hypoketotic hypoglycemia with decreased KB/FFA ratio, moderate hepatomegaly, and normal lactate levels upon prolonged fasting (15 hours), with normal mFAO in cultured skin fibroblasts 38 .
A combination of progressive neurological complaints, Reye-like syndrome with convulsions, and abnormal organic aciduria (i.e. ethylmalonic acid (EMA), glutaric acid, and N-acylglycine excretion, resembling MADD), with normal [9,10(n)-3 H 2 ]-tetradecanoic acid oxidation in cultured skin fibroblasts has also been described in complex IV deficient patients 40, 41 .
In vitro studies in cultured skin fibroblasts from patients with an isolated complex IV deficiency underlined the reported clinical symptoms, as C 16:0 -oxidation was lowered when measured by tritium release from [9,10(n)-3 H 2 ]-C 16:0 36 . Acylcarnitine profiles in cultured skin fibroblasts were MADD-like 37 .
Overall, MADD-like acylcarnitine profiles and hypoglycemia were most commonly seen in patients with an OXPHOS defect and concurrent mFAO dysfunction ( Figure 3 ).
DEFECTS IN MFAO ASSOCIATED wITh SECONDARy OxPhOS DySFuNCTION
When considering the close biochemical interrelations in mitochondrial metabolism, primary mFAO defects may cause secondary dysfunctional OXPHOS (Figure 4 ). The experimental focus of most studies was on the "intoxication" phenotype resulting from accumulation of mFAO intermediates, the severity of which largely depends on the chain-length of the accumulating mFAO intermediates 42 . 
OXPHOS defect
Long-chain mFAO defects
With regards to long-chain mFAO defects, only patients with isolated LCHAD deficiency or with MTP deficiency have been described to present clinically with symptoms such as lactic acidosis, retinopathy, cardiomyopathy, muscle hypotonia, hepatosteatosis, and hypoglycemia, combined with elevated plasma long-chain hydroxyacylcarnitines, low free carnitine concentrations, and abnormal organic aciduria (with elevated concentrations of C 6 -C 10 dicarboxylic acids, and both saturated and unsaturated adipic and suberic acids) [43] [44] [45] [46] . One case report described a patient who presented with unresponsiveness to intravenous glucose during gastroenteritis with hypoglycemia, increasing lactate concentrations and lactate/pyruvate ratio upon glucose administration, and improvement upon administration of vitamins B 1 , C, K 1 , and riboflavin. These symptoms are highly indicative for defective OXPHOS. In a skeletal muscle biopsy enzyme activities of complexes I, II, III, and IV were hardly detectable 43, 45 . Similar findings were reported in post-mortem studies in muscle tissue of LCHAD deficient patients (all homozygous for the G1528C mutation) 46 . 
Long-chain mFAO defect
Inhibition
When digitonin-permeabilized skin fibroblasts from healthy volunteers were incubated with C 16 -CoA and intermediates of C 16 -CoA oxidation (hexadec-2-enoyl-CoA, 3-hydroxyhexadecanoyl-CoA, 3-ketohexadecanoyl-CoA, and 3-hydroxytetradecanoic acid), succinate-and glutamate-driven OXPHOS were inhibited in a concentration-dependent manner [47] [48] [49] [50] [51] . Decreased formation of malate from succinate most likely resulted from direct inhibition of the dicarboxylate carrier by C 16 -CoA or its β-oxidation intermediates 48 . Additionally, ADP-induced respiration was found to be inhibited, most likely due to direct inhibition of the mitochondrial adenine nucleotide transporter (ANT) by longchain acyl-CoA esters. 50, 52 .
Finally, in vitro studies showed uncoupling effects of the long-chain mFAO fatty acids C 16:0 , 3-hydroxydodecanoic acid, 3-hydroxytetradecanoic acid and 3-hydroxyhexadecanoic acid in rat liver, brain and heart mitochondria 51, 53, 54 . In uncoupled mitochondria, the proton gradient is not entirely used for ATP production, but generates heat 55 .
Medium-chain mFAO defects
Cases of MCAD deficiency leading to clinical presentations corresponding to secondary OXPHOS defects have not been described in literature, whereas in vitro studies showed various associations between accumulation of medium-chain mFAO intermediates and hampered OXPHOS. These associations, however, were observed mostly at non-physiological concentrations of these intermediates that are rarely seen in patients with MCAD deficiency.
In vitro studies in homogenates of rat cerebral cortex revealed an uncoupling effect of octanoic acid (OA), decanoic acid (DA), and cis-4-decenoic acid (cDA) on mitochondrial function 56, 57 . Only cDA inhibited 2,6-dichloroindophenol reduction by succinate (complex II), cytochrome c reduction by succinate (complex II + CoQ + complex III), and oxidation of cytochrome c (complex IV) at concentrations that can sporadically be found in plasma of MCAD deficient patients during metabolic crisis (0.1 -0.25 mM) 58 . However, synergism between these three metabolites could not be excluded 58 . OA has further been described to affect the intramitochondrial ATP/ADP ratio and lower the P/O ratio (amount of ATP generated per reduced oxygen atom in OXPHOS) 59, 60 . In vitro studies in isolated bovine heart cells reported complex III inhibition by octanoyl-CoA in a concentration-dependent manner, possibly due to prevention of reduction of cytochrome b 61 . Octanoyl-CoA was furthermore found to inhibit PDHc activity 61 . Octanoyl-carnitine, which most commonly accumulates in blood of patients with MCAD deficiency, did not exert these effects 59,61 .
Short-chain mFAO defects
As for MCAD deficiency, no case reports presenting patients with SCAD deficiency and associated OXPHOS dysfunction have been described in literature. However, it should be noted that the phenotypical spectrum varies considerably. Due to the position of SCAD in mFAO, where MCAD can largely compensate for deficient SCAD, it is difficult to understand the observed symptoms in these patients 3 . Consequently, it is even questionable whether SCAD deficiency can be considered an inborn error of metabolism. OXPHOS impairment by short-chain mFAO intermediates has only been observed and 2,6-dichloroindophenol reduction by succinate (complex II) were inhibited at higher concentrations 64 . In rat liver mitochondria, short-chain fatty acids have been reported to decrease the P/O ratio in a concentration-dependent manner upon incubation. However, the effect of butyrate was weaker than the effect of medium-chain fatty acids at equal concentrations 60 . PDHc was inhibited by acyl-CoA esters in a chain-length specific manner, with short-chain monocarboxylic acyl-CoAs exerting the strongest effect. This latter finding has a physiological explanation, as acetyl-CoA is a product of PDHc, which allosterically inhibits PDHc and thereby prevents overload of the TCA cycle.
As for medium-chain length metabolites, short-chain dicarboxylic acyl-CoAs or acylcarnitines were not found to inhibit OXPHOS 28, 61 .
Multiple acyl-CoA dehydrogenase deficiency
Patients with MADD were defined as patients with biochemical characteristics of MADD due to impairment of ETFα, ETFβ or ETF-DH function. A subset of the patients carrying mutations in ETF-DH has been described to have milder riboflavin-responsive forms of MADD 7 . Several studies have described cases of riboflavin-responsive MADD (not due to a riboflavin-transporter defect) with lowered activities of complexes I and II of the ETC and secondary UQ deficiency [65] [66] [67] [68] . Riboflavin supplementation was found to induce complete recovery of the clinical symptoms, with improved activities of the ACADs, and normalized activities of complexes I and II. Decreased availability of FAD was found to be the main cause for the accompanying OXPHOS dysfunction in MADD [65] [66] [67] .
In summary, inhibition of ANT due to the accumulating intermediates, with secondary dicarboxylate carrier and PDHc dysfunction were most commonly reported in studies on concurrent OXPHOS dysfunction in response to an mFAO defect.
ThE ROLE OF SECONDARy CELLuLAR RESPONSES
In general, clinical presentations of defects in OXPHOS or mFAO are distinguishable separate entities.
However, based on the close biochemical interrelations, one would expect to regularly see clinical presentations of associations between OXPHOS and mFAO defects. As the concurrence of OXPHOS and mFAO is sporadically displayed in a clinical presentation, and the observed clinical presentations are very heterogeneous, these episodes cannot be solely explained by primary biochemical linkages.
We hypothesize that the enzyme insufficiencies or deficiencies that were discussed in this review may lead to improper activation of signaling pathways due to alterations in metabolite concentrations, and ultimately to an insurmountable obstacle causing failure to reach normal homeostasis.
Even though a new steady state will eventually be reached, it will be pathologic in nature. It should be realized that metabolic functioning is tightly linked to metabolic regulation. Metabolic diseases result in abnormal intracellular steady-state concentrations of essential metabolites. Often normal oxygen uptake rates have been described in patients with mitochondriopathies 69 . As a result, supply of redox equivalents to reduce oxygen from NADH and FADH 2 via ETC will remain normal, as will the flux through the TCA cycle. The partially deficient enzyme, however, can only work at normal speed if its reduced catalytic capacity is compensated by increased substrate and/or decreased product concentrations. The cell will recognize the new steady-state as a disrupted homeostasis and a counter-regulatory response may be mounted via signal transduction and/or gene expression. We therefore hypothesize that these secondary cellular responses to changes in the metabolome are an important, and currently under-exposed, contributor to the development of a clinical phenotype.
Data underlining this hypothesis were recently presented in a study on secondary cellular responses in tissue samples of patients with a confirmed complex I deficiency. The data were not linked yet to mFAO impairment. Zhang et al. studied the transcriptome by microarray analysis in muscle biopsies and cultured skin fibroblasts 69 . By means of this unbiased approach a highly tissue-specific response was detected, with alterations at the level of the global transcriptome and in parallel in the activity of nutrient-sensing signaling networks of i.e. mTORC1, AMPK, SIRT, FOXO and PPAR. Alterations in these networks resulted in conflicting anabolic and catabolic responses occurring simultaneously.
Most strikingly, intervening in these secondary cellular responses by treating complex I deficient cultured skin fibroblasts with nicotinic acid, a precursor for NAD + , activated the NAD + -dependent protein deacetylase SIRT, PPAR, mTORC1 and AMPK signaling. This led to normalization of the activity of these networks, and improved cellular respiratory capacity, without affecting the severity of the OXPHOS defect. Similar effects were seen in mice with cardiac complex I deficiency (due to knockout of cardiac Ndufs4) after treatment with nicotinamide mononucleotide, another NAD + precursor 70 . It should however be noted that these effects may in part be due to alterations in the primary biochemical reactions, because changes in NADH/NAD + ratio will directly affect metabolism as well. With regards to primary mFAO defects, altered mTORC1 signaling was found to determine phenotype severity in zebrafish with MADD due to inactivation of the etfa gene, coding for ETFα protein.
Etfa deficient zebrafish showed similarities with MADD-patients both biochemically and clinically.
Acylcarnitine profiles were abnormal, and fatty liver was observed. Additionally, hyperplastic neural progenitor cells, hepatocytes and kidney tubule cells were observed. Increased mTORC1 signaling was observed with cellular enlargement and proliferation, which was abolished by rapamycin 73 .
The authors speculate that the persistent increase of leucine, activator of mTORC1 and substrate of isovaleryl-CoA dehydrogenase, which needs ETFa for its activity, might be central in eliciting the secondary cellular response in MADD 73 .
Circumstantial evidence on a potential role for secondary cellular responses in determining the clinical phenotype in mFAO defects was also found in LCAD-deficient mice 74 . In this mouse model, amino acid metabolism was intrinsically disturbed, possibly also due to altered mTORC activation resulting from the mFAO dysfunction.
In OXPHOS and mFAO defects, dietary treatment forms the basis of therapy. Administration of high doses of intravenous glucose is necessary in patients with a defect in mFAO who are in a metabolic crisis, whereas this treatment may lead to an undesired increased lactate concentration and aggrava- 
CONCLuSION AND FuTuRE PERSPECTIVES
In this review we addressed the question why defects in OXPHOS only sporadically behave as mFAO defects and vice versa. Inborn errors of metabolism are complex traits 1 . The sporadic nature of clinical phenotypes displaying the concurrence of OXPHOS and mFAO defects is an illustration of this principle. In this review, we discussed the published reports on clinical presentations associated with combined defects in both OXPHOS and mFAO. Based on the discussed results we can conclude, albeit preliminary, that instead of the primary biochemical links, secondary cellular responses may well be the criterion to determine whether an individual will be at-risk for a metabolic crisis involving both OXPHOS and mFAO. Since nutrient-sensing signaling networks integrate signals from many sources, outside and inside the cell by complex feed-forward and feed-backward responses, changes in the metabolic state of affected cells or conditions in the environment of these cells may well explain the accidental nature of these metabolic crises. This problem asks for studies from a cellular point of view with an unbiased approach i.e. an -omics approach (entailing respectively, metabolomics, proteomics, and genomics at the level of the secondary signaling pathways) and careful histology 77 .
From the point of view of OXPHOS defects, application of these unbiased approaches has resulted in identification of new inborn errors of phospholipid metabolism affecting OXPHOS [see 78 for a review]. Exome sequencing followed by Sanger sequencing identified mutations in the gene coding for an enzyme involved in phospholipid remodeling (SERAC1), which resulted in OXPHOS defects 79 . Integrative analysis of the results of various -omics technologies will be the next step.
Although not yet applied in clinical practice, combinations of metabolomics and genomics have been used in studies of population cohorts with promising results 80, 81 . What is however missing are 'phenomes':
thorough, coherent and exact descriptions of patient clinical characteristics 82, 83 . The availability of structured phenotypic information in genomic databases will improve clinical care 84 .
In conclusion, the study of secondary cellular responses that results from primary OXPHOS defects has now started. Most strikingly, these studies hold promise to genuinely new approaches for diagnosing and treating patients with OXPHOS and mFAO defects. It calls for the more integrative approach of systems medicine with implementation of medical practice driven by clinical investigations, -omics technologies and computational models.
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